Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amyris Inc    AMRS

AMYRIS INC (AMRS)
Mes dernières consult.
Most popular
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Amyris Inc : Lundin Law PC Announces a Securities Class Action Lawsuit against Amyris, Inc. and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2017 | 05:47am CEST

LOS ANGELES, CA / ACCESSWIRE / May 19, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Amyris, Inc. ("Amyris" or the "Company") (NASDAQ: AMRS) concerning possible violations of federal securities laws. Investors, who purchased shares between March 2, 2017 and April 17, 2017, inclusive (the "Class Period"), should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that during the Class Period, Amyris made false and/or misleading statements and/or failed to disclose: that in the first quarter of 2017, the Company made a decision to take an equity stake in one of Blue California's affiliates that focused on the sweetener market instead of cash payment under the license agreement; that due to this decision, Amyris would be unable to recognize $10 million in fourth quarter and fiscal year 2016 revenue from the license agreement with Blue California; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. Following this news, Amyris' stock price fell materially, which caused investors harm according to the Complaint.

Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles devoted to upholding shareholders' rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/

SOURCE: Lundin Law PC


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYRIS INC
09/07 AMYRIS : to Present at Rodman and Renshaw 19th Annual Global Investment Conferen..
09/06 Amyris to Present at Rodman & Renshaw 19th Annual Global Investment Conferenc..
08/18 FRIDAY SECTOR LEADERS : Oil & Gas Refining & Marketing, Education & Training Ser..
08/14 AMYRIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
08/14 AMYRIS : Delivers another Strong Quarter with Revenue of $25.7 Million and Produ..
08/11 AMYRIS : Announces Closing of $50 Million in Second Tranche Equity Financing Ful..
08/11 AMYRIS, INC. (NASDAQ : AMRS) reported earnings of ($1.36) per share missing Wall..
08/10 AMYRIS : posts 2Q profit
08/10 AMYRIS, INC. (NASDAQ : AMRS) Files An 8-K Results of Operations and Financial Co..
08/10 AMYRIS, INC. : Results of Operations and Financial Condition, Financial Statemen..
More news
News from SeekingAlpha
05/19 Amyris (AMRS) Investor Presentation - Slideshow
05/15 Amyris' (AMRS) CEO John Melo on Q1 2017 Results - Earnings Call Transcript
05/15 Amyris misses by $0.04, misses on revenue
05/14 Notable earnings after Monday?s close
04/20 INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Apollo Global, Pulse Biosciences, Acacia ..
Financials ($)
Sales 2017 119 M
EBIT 2017 -62,0 M
Net income 2017 -65,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 1,10x
Capi. / Sales 2018 0,68x
Capitalization 132 M
Chart AMYRIS INC
Duration : Period :
Amyris Inc Technical Analysis Chart | AMRS | US03236M1018 | 4-Traders
Technical analysis trends AMYRIS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 9,25 $
Spread / Average Target 164%
EPS Revisions
Managers
NameTitle
John G. Melo President, Chief Executive Officer & Director
Geoffrey M. Duyk Chairman
Kathleen Valiasek Chief Financial Officer
Joel Cherry President-Research & Development
Louis John Doerr Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMYRIS INC-67.12%132
HENKEL0.13%55 706
ECOLAB INC.12.04%38 004
SIKA49.53%16 232
SYMRISE11.71%10 022
JOHNSON MATTHEY PLC9.74%9 119